Biocryst Pharmaceuticals (BCRX) EPS (Basic) Growth (1y) (2011 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) EPS (Basic) Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 65.24% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -636.10% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 7.74% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -4.72% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 87.85% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 322.67% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -84.77% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.29 Bn | 1.94 Bn | 214.41 Mn | 1,169.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,169.30% |
| Mar 31, 2026 | -1,944,998.80% |
| Dec 31, 2025 | 1,003.53% |
| Sep 30, 2025 | 190.49% |
| Jun 30, 2025 | 139.53% |
| Mar 31, 2025 | 100.09% |
| Dec 31, 2024 | 59.64% |
| Sep 30, 2024 | 64.42% |
| Jun 30, 2024 | 84.59% |
| Mar 31, 2024 | 39.32% |
| Dec 31, 2023 | 16.54% |
| Sep 30, 2023 | 16.54% |
| Jun 30, 2023 | -25.60% |
| Mar 31, 2023 | 29.50% |
| Dec 31, 2022 | -287.69% |
| Sep 30, 2022 | 30.44% |
| Jun 30, 2022 | -30.76% |
| Mar 31, 2022 | -4.41% |
| Dec 31, 2021 | 71.12% |
| Sep 30, 2021 | 47.52% |